In a study conducted by Aurbach et al., gradual administration of exogenous fibroblast growth factor 9 (FGF9) led to an increase in anxiety- and depression-like behaviors and simultaneously decreased FGFR1 expression in the dentate gyrus [133]. Here, FGF9 is linked to depressive disorder.